Table 3.
Main tumor model parameters and their associated values. All other tumor-related parameters are as in (Wu et al., 2013).
| Parameter | Value | Reference |
|---|---|---|
| Tumor proliferation rate | 1 day−1 | (Curtis et al., 2016) |
| Tumor necrosis threshold | 0.5700 | (van de Ven et al., 2012) |
| Tumor hypoxic threshold | 0.5750 | (van de Ven et al., 2012) |
| Oxygen diffusivity | 1 (a) | (Wu et al., 2013) |
| Oxygen transfer rate from vasculature | 5 (a) | (Wu et al., 2013) |
| Oxygen uptake rate by proliferating tumor cells | 1.5 (a) | (Wu et al., 2013) |
| Oxygen uptake rate by hypoxic tumor cells | 1.3 (a) | (Wu et al., 2013) |
| Oxygen uptake rate by tumor microenvironment | 0.12 (a) | (Wu et al., 2013) |
| Oxygen decay rate | 0.35 (a) | (Wu et al., 2013) |
| CDDP drug effect | 2.7E5 | Calibrated to data in (Curtis et al., 2016) |
| CDDP decay rate | 0.5hr half-life | (Leighl, 2012) |
| CDDP in vitro IC50 (48 hrs.) for A549 cells (spheroid) | 26.6 μM | (Curtis et al., 2016) |
| CDDP diffusivity | 0.5 (a) | (Sinek et al., 2009) |
| dFdC drug effect | 1.6E4 | Calibrated to data in (Chougule et al., 2011) and (Godugu et al., 2013) |
| dFdC decay rate | 1.0hr half-life (average) for short (<70 min) infusion | (Eli Lilly, 2017) |
| dFdC in vitro IC50 (72 hrs.) for A549 cells (spheroid) | 77.5 μM | (Chougule et al., 2011) and (Godugu et al., 2013) |
| dFdC diffusivity | 0.5 (a) | (b) |
(a)
Value is rescaled by the square of the simulation system characteristic length (1 cm) and divided by the system characteristic time (1 sec) multiplied by the oxygen diffusivity (Nugent and Jain, 1984) (1 × 10−5 cm2 s−1). CDDP: cisplatin; dFdC: gemcitabine.
(b)
Assumed as a first approximation due to molecular weight and hydrophilicity to be comparable to CDDP.